Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September
Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025
OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026
Seasonal flu (ARCT-2138) showed positive Phase 1 results
BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025
Investor conference call at 4:30 p.m. ET today
Cash, cash equivalents and restricted cash were $253.4 million as of June 30, 2025, and $293.9 million on December 31, 2024. Based on the current pipeline and programs, the cash runway remains extended into 2028.
Earnings Call: Monday, August 11, 2025 @ 4:30 p.m. ET
- Domestic: 1-800-274-8461
- International: 1-203-518-9814
- Conference ID: ARCTURUS
- Webcast: Link
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.